ReproCell Stock

ReproCell Enterprise Value

The Enterprise Value (EV) of ReproCell (4978.T) as of Sep 4, 2026 is 11.51 B JPY. In the previous year, Enterprise Value (EV) was 8.88 B JPY — a change of 29.56% (higher).

Enterprise Value

11.51 BJPY

YoY

29.56%

Last updated:

Enterprise Value (EV) of ReproCell is 2026 11.51 B JPY. Enterprise Value (EV) of ReproCell was 2025 8.88 B JPY. It decreases by 29.56% higher compared to the previous year.

The ReproCell Enterprise Value history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Enterprise Value
Date
Enterprise Value
Jan 1, 2018
9.96 B JPY
Jan 1, 2019
9.81 B JPY
Jan 1, 2020
10.34 B JPY
Jan 1, 2021
10.93 B JPY
Jan 1, 2022
10.89 B JPY
Jan 1, 2023
9.07 B JPY
Jan 1, 2024
8.88 B JPY
Jan 1, 2025
11.51 B JPY
The ReproCell Enterprise Value history
YEAREnterprise ValueYoY
11.51 BJPY+29.56%
8.88 BJPY-2.07%
9.07 BJPY-16.70%
10.89 BJPY-0.37%
10.93 BJPY+5.65%
10.34 BJPY+5.37%
9.81 BJPY-1.42%
9.96 BJPY-1.62%
10.12 BJPY-0.10%
10.13 BJPY-4.52%
10.61 BJPY+2.44%
10.36 BJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Enterprise Value (EV) of ReproCell is 11.51 B JPY in 2026.

Enterprise Value (EV) of ReproCell changed from 8.88 B JPY to 11.51 B JPY, representing a 29.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Enterprise Value (EV) ReproCell since 2006 – with annual values, charts, and detailed analysis.

Enterprise Value represents the total value of a company, including both equity and debt, minus cash. It provides a more comprehensive picture than market capitalization alone.

EV = Market Capitalization + Total Debt - Cash & Equivalents

To evaluate Enterprise Value (EV)'s JPY, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Enterprise Value (EV).

A 'good' JPY varies by industry and company stage. On Eulerpool, you can compare Enterprise Value (EV)'s ReproCell with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — ReproCell

All Key Metrics — ReproCell